Difference between revisions of "Dasatinib (Sprycel)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
| + | Also known as BMS-354825. | ||
| + | |||
==General information== | ==General information== | ||
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_sprycel.pdf Dasatinib (Sprycel) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/dasatinib.pdf Dasatinib (Sprycel) package insert (locally hosted backup)]</ref> | Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_sprycel.pdf Dasatinib (Sprycel) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/dasatinib.pdf Dasatinib (Sprycel) package insert (locally hosted backup)]</ref> | ||
| Line 4: | Line 6: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 06:37, 10 March 2012
Also known as BMS-354825.
General information
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Dasatinib (Sprycel) patient drug information (Chemocare)[3]
- Dasatinib (Sprycel) patient drug information (UpToDate)[4]